Skip to main content
. 2020 Sep 15;3(9):e2016858. doi: 10.1001/jamanetworkopen.2020.16858

Figure. Adverse Drug Events (ADEs) Associated With Current Opioid Use vs No Current Opioid Use After Breast Cancer Treatment.

Figure.

Point estimates (boxes) and 95% CIs (whiskers) were estimated using modified Poisson generalized estimating equations for the association between any current opioid exposure vs no current opioid exposure on ADE outcomes in the year after completing active breast cancer treatment. The substance misuse–related ADE model was estimated using modified Poisson clustering on individual because of lack of convergence in generalized estimating equations. Estimates adjusted for age, race/ethnicity (ie, White, Black, Hispanic, or other), low-income subsidy receipt, comorbidity score (ie, 0, 1, or ≥2), cancer stage (ie, 0, I, II, or III), tumor size (ie, ≤2 cm, <2 to <5 cm, ≥5 cm, or unknown size), breast surgical treatment (ie, mastectomy, partial mastectomy, lymph node surgery, tumor biopsy, or none), use of hormonal therapy, use of radiation, use of adjuvant chemotherapy, use of any chemotherapy, any use of trastuzumab, any use of a taxane, and any use of doxorubicin. Vertical dotted line indicates reference null adjusted risk ratio of 1.00.